Comment: Adverse-Effect Profile of Sustained-Release Niacin

Abstract

Get full access to this article

View all access options for this article.

References

Jungnickel

Maloley

. Extended-release niacin not problem free (letter). Am J Hosp Pharm 1991; 48: 237–8.

Clementz

Holmes

. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol 1987; 9: 582–4.

Hodis

. Acute hepatic failure associated with the use of low-dose sustained-release niacin (letter). JAMA 1990; 264: 181.

Mullin

Greenson

Mitchell

. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989; 111: 253–5.

Knopp

Ginsberg

Albers

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 1985; 34: 642–50.

Christensen

Anchor

Berge

Nicotinic acid treatment of hypercholesterolemia: Comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA 1961; 177: 546–50.

Henkin

Johnson

Segrest

. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA 1990; 264: 241–3.

Etchason

Miller

Squires

Niacin-induced hepatitis: A potential side effect with low-dose time-release niacin. Mayo Clin Proc 1991; 66: 23–8.

The Expert Panel. Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36–69.

10.

Kowalski

. The 8-week cholesterol cure. New York: Harper & Row, 1987.